Vivakor, Inc. 10-Q Summary: Quarter Ended September 30, 2010
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Vivakor, Inc., a trans-disciplinary biomedical company focused on the discovery, development, and commercialization of medical devices and pharmaceuticals. The report covers the three and nine-month periods ended September 30, 2010. The Company is classified as a "smaller reporting company" and a "shell company" status is denied. As of November 17, 2010, there were 137,275,494 shares of Common Stock outstanding.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2010 | 9 Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenues | $212,629 | $143,347 |
| Net Loss (Attributable to Vivakor) | $(1,270,303) | $(1,396,986) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.03) |
| Cash and Cash Equivalents (End of Period) | $561 | $69,299 |
| Net Cash Used in Operating Activities | $(343,585) | $(147,340) |
| Net Cash Provided by Financing Activities | $145,500 | $70,215 |
| Total Current Liabilities | $1,740,333 | $2,216,301 |
| Accumulated Deficit | $(4,998,879) | $(3,420,661) |
Liquidity Note: The Company reported only $561 in cash and cash equivalents as of September 30, 2010, down from $187,646 at year-end 2009. Current liabilities significantly exceed current assets.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue increased by approximately 48% year-over-year for the nine-month period. This was driven by new license fee revenue ($76,979) and increased product sales ($135,650 vs. $30,435). However, grant revenue dropped to zero in 2010 after an NIH grant was exhausted in 2009.
- Operating Expenses: General and Administrative (G&A) expenses increased significantly to $1,114,419 (from $623,509) due to increased consultant fees and full-time executive compensation. Conversely, Research and Development (R&D) expenses decreased to $714,393 (from $870,838) due to reduced headcount and funding constraints.
- Non-Operating Items: The 2010 results include a significant non-cash gain of $343,260 from the settlement with the former CEO, who forgave accrued compensation. This was offset by a $64,678 loss on the disposition of fixed assets due to office relocations.
- Debt Structure: The Company converted a significant portion of its debt into equity. A $505,058 note payable from 2009 was fully converted to common stock in May 2010. New convertible notes totaling approximately $167,500 were issued during the period.
Outlook, Risks, and Management Commentary
Going Concern: Management explicitly states substantial doubt regarding the Company's ability to continue as a going concern. The Company does not have sufficient cash to fund operations for the next twelve months. Continued existence depends on raising additional capital through equity or debt offerings, which is not guaranteed.
Capital Formation: The Company is in the midst of a capital formation activity initiated in August 2009. While some cash proceeds were received, a significant portion of the consideration was in the form of notes receivable ($1,040,541 remaining balance), which are accruing interest and have no assurance of collection.
Operational Risks:
- Liquidity Crisis: With only $561 in cash, the Company faces immediate liquidity risks.
- Dilution: The Company has issued and reserved millions of shares for consultants, debt conversions, and future offerings, leading to significant shareholder dilution.
- Revenue Reliance: Revenue is heavily dependent on a single license agreement with Regeneca International, Inc. for the VivaBoost product.
Unusual Items: The filing notes the resignation of the former CEO and the subsequent sale of the "VivaBlend" formula rights to him for $1.00. Additionally, the Company is awaiting FINRA approval to distribute a dividend of Regeneca shares to its stockholders.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and any new financing secured since September 30, 2010, given the reported balance of $561.
- Notes Receivable Collectability: Assess the likelihood of collecting the $1,040,541 in notes receivable from the capital formation activity, which are currently accruing interest on a month-to-month basis.
- Debt Conversion Terms: Review the terms of the outstanding convertible notes (approx. $107k principal plus conversion features) which carry anti-dilution provisions and high interest accretion.
- Regeneca Agreement Status: Confirm the status of the $5 million purchase commitment from Regeneca International and the progress of the pending FINRA dividend distribution.
- Share Count: Monitor the rapid increase in outstanding shares due to debt conversions and consultant compensation, which impacts per-share value.